Business Context and Reporting Period
This Form 8-K filing by NanoViricides, Inc. (NNVC) covers events occurring on February 7, 2020, and February 10, 2020. The report details significant changes to the Company's Board of Directors, including the appointment of a new independent director and the resignation of an existing director.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.
Material Changes
- Board Appointment: Effective February 7, 2020, Makarand "Mak" Jawadekar, Ph.D., was appointed as an Independent Member of the Board of Directors. He will serve on the Audit, Compensation, and Nominating Committees.
- Board Resignation: Effective February 10, 2020, James Sapirstein resigned from the Board of Directors and its Audit, Nominating, and Compensation Committees.
- Reason for Resignation: Mr. Sapirstein's resignation was due to his appointment as President and CEO of AzurRX BioPharma, Inc. He stated there was no disagreement with the Company regarding operations, policies, or practices.
Outlook, Risks, and Management Commentary
Management highlighted Dr. Jawadekar's extensive background, including over 35 years in the pharmaceutical industry with Pfizer and experience in alliance management, drug delivery, and global R&D. The Company believes his expertise qualifies him to serve as an independent director. No specific financial guidance, risks, or contingencies were disclosed in this filing.
Investor Verification Checklist
- Verify the effective dates of the board changes (Feb 7 for appointment, Feb 10 for resignation).
- Confirm Dr. Jawadekar's current roles on other public company boards (Preveceutical Medical Inc., Cardax, Inc.) and advisory boards.
- Review the Form of Director Retainer Agreement (Exhibit 10.1) for compensation details regarding the new appointment.
- Check subsequent filings for any financial impact related to the leadership transition.